je.st
news
Tag: expression
Epson Expression Home XP-420 Small-in-One
2015-06-17 19:02:08| PC Magazine: New Product Reviews
Meant primarily as a multifunction printer for home use, the modestly priced Epson Expression Home XP-420 Small-in-One offers lots of features and better-than-expected text quality.
Tags: home
expression
epson
smallinone
Maternal diet before conception may affect baby's DNA expression
2015-06-12 08:00:21| Oil & Gas - Topix.net
"Because this gene plays a key role in controlling response to viral infections and offering protection against certain cancers, the potential implications are enormous," said Professor Andrew Prentice. A mother's environment and dietary habits around the time of conception could permanently change the function of genes influencing the risk of diseases in her child, say researchers.
Tags: affect
expression
dna
diet
New Findings Show Durable Anti-Tumor Activity with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status
2015-05-29 20:06:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Results from KEYNOTE-012, the First and Largest Study to Date of an Anti-PD-1 Therapy in Head and Neck Cancer, to be Presented at 2015 ASCO Annual Meeting KEYTRUDA Monotherapy Achieved Overall Response Rate of 25 Percent in Heavily Pre-treated Patients Merck is Advancing a Broad Head and Neck Clinical Program for KEYTRUDA with Five Clinical Trials, Across Multiple Lines of Therapy and in Combination with Other Agents KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: show
advanced
status
head
Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA (pembrolizumab)
2015-05-28 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & SEATTLE Collaboration Builds on Mercks R&D and NanoStrings Biomarker Development Leadership Positions in Immuno-Oncology Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in multiple tumor types. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orNanoString Investor/Media Relations:Leigh Salvo, 415-513-1281 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NSTG Exchange: NASDAQ read more
Tags: for
research
development
program
Candente Gold Receives Expression of Interest for Processing Agreement of Mexico Mine Tailings
2015-02-12 13:26:19| Paper - Topix.net
The EOI was received by the Company from Minera Arcu S.A. de C.V , which has extensive experience and technical expertise in developing and operating tailings reprocessing projects in Mexico. In addition to their expertise, Minera Arcu proposes to invest capital required in respect of the acquisition and installation of equipment related to both testing and operating of the mineral concentration and recovery processes for the Tailings.
Tags: interest
agreement
gold
mexico
Sites : [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »